For millions of patients, their quality of life is severely impacted due to the complexity of their conditions and difficult–to-perform surgeries.
We saw the potential to expand treatment options for patients by empowering more surgeons to practice microsurgery and supermicrosurgery in open, soft tissue procedures. We knew this would only be possible by dramatically advancing technology to better support surgeons who work tirelessly on vessels and nerves that are less than a few millimeters in diameter. These surgeries can benefit from more accuracy and precision, which ultimately lead to less trauma and faster recovery. But only a limited number of surgeons are trained in these techniques.
Our innovation pathway was clear; only a miniaturized articulated instrument could repair tiny, delicate anatomy. We focused first on developing the world’s smallest wristed instrument. Then we created the only customized, robotic platform capable of delivering the precise movement such a small instrument demands. This is the Symani Surgical System, proof that our relentless commitment to innovation is changing the impossible.
MMI History
2015
MMI founded
MMI is born in Pisa, Italy by founders with deep surgical robotic expertise and experience who collaborated to solve unmet patient needs.
2016
Funds raised
Seed financing secures $2M for startup
2017
Preclinical work begins
First animal study utilizing Symani System prototype conducted to demonstrate clinical relevance
2018
Series A financing
MMI raises $24M to build robot, prepare for regulatory submissions and EU market launch
2019
First regulatory approval in Europe
Symani Surgical System receives CE mark
Preclinical evidence in animal model points to better outcomes with 2x lower thrombosis rate and decreased incidence of inflammatory reaction across all vessel sizes
2020
Symani first human use
Symani Surgical System launched in Europe with first in-human use completed
2021
EU installations begin
First commercial installation of the Symani Surgical System at the University Hospital Salzburg
2022
Momentum continues
Series B financing raises $75M to accelerate clinical trials and global commercialization
Major expansion completed at European Headquarters to support growth
Corporate redomicile to U.S.
Launch of supermicrosurgery instruments designed to connect vessels under one millimeter in diameter
2023
Adoption increases
Symani Surgical System procedure volume growth
PRIMO post market clinical study program expansion
2024
Series C funding
$110M round led by Fidelity Management & Research Company to support commercialization of Symani in high-growth markets, marking the largest ever investment in microsurgery innovation
2024
U.S. regulatory approval
Symani Surgical System receives FDA De Novo Authorization, becoming the only commercially available system in the U.S. for reconstructive microsurgery
2024
First U.S. clinical cases
Completion of first U.S. in-human robotic-assisted microsurgical procedures with the Symani Surgical System mark the start of a new era of soft tissue open surgery
Our Culture
At MMI, we know that our people are our greatest assets and strength. We pride ourselves on creating a culture of transparency, respect, inclusion, and fun.
Our People
The team at MMI inspires each other to make a difference for patients with complex conditions. We see it as our duty to make more treatment options more widely available.
Careers at MMI
Want to make a real difference? We’re seeking purpose-driven individuals to join our team.
MMI
5022 Gate Parkway,
Building 500,
Jacksonville, FL 32256
5022 Gate Parkway,
Building 500,
Jacksonville, FL 32256
Product Information: connect@mmimicro.com
Symani Support: techsupport@mmimicro.com
The Symani Surgical System is authorized for use in the U.S. by the FDA and is a CE marked medical device. Clinical indications vary by geography. Refer to global indications for more information. © 2024 Medical Microinstruments, Inc. All Rights Reserved.